Wang Xujia, Guan Shuaimeng, Zhang Kun, Li Jingan
Shanghai Junshi Biosciences Co., Ltd., Shanghai 200237, P. R. China.
School of Life Science, Zhengzhou University, 100 Science Road, Zhengzhou 450001, P. R. China.
ACS Omega. 2020 May 1;5(18):10395-10400. doi: 10.1021/acsomega.0c00283. eCollection 2020 May 12.
Benlysta is a new drug approved by the US Food and Drug Administration (US FDA) in 2019 for the treatment of systemic lupus erythematosus. In this study, we loaded the benlysta in the traditional sodium alginate (SA) hydrogel to investigate the potential application of the drug-loaded hydrogel for skin dressing or hypodermic drug. Live/dead staining images and the CCK-8 results showed that the benlysta-loaded hydrogel could promote the growth of human epidermal cells (HaCat), fibroblasts (L929), and endothelial cells while inhibiting the aggregation of inflammatory cells (macrophages). In addition, the hydrogel degradation and drug release are slow and controllable, and the gel time of drug-loaded hydrogel can be adjusted by adding sodium alginate ratios according to the requirement. In summary, we prepared a time-dependent drug-loaded hydrogel for potential application in the treatment of skin injury that may be caused by other diseases.
贝利尤单抗是一种于2019年获美国食品药品监督管理局（US FDA）批准用于治疗系统性红斑狼疮的新药。在本研究中，我们将贝利尤单抗负载于传统的海藻酸钠（SA）水凝胶中，以研究载药水凝胶在皮肤敷料或皮下给药方面的潜在应用。活/死细胞染色图像和CCK-8结果表明，载有贝利尤单抗的水凝胶可促进人表皮细胞（HaCat）、成纤维细胞（L929）和内皮细胞的生长，同时抑制炎性细胞（巨噬细胞）的聚集。此外，水凝胶的降解和药物释放缓慢且可控，载药水凝胶的凝胶时间可根据需要通过添加海藻酸钠比例进行调节。总之，我们制备了一种具有时间依赖性的载药水凝胶，其在治疗可能由其他疾病引起的皮肤损伤方面具有潜在应用价值。
